Legal & General Group Plc grew its holdings in Celgene Corporation (NASDAQ:CELG) by 4.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,751,507 shares of the biopharmaceutical company’s stock after buying an additional 163,884 shares during the quarter. Legal & General Group Plc owned approximately 0.48% of Celgene Corporation worth $487,210,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in Celgene Corporation during the 1st quarter valued at approximately $118,000. Acropolis Investment Management LLC bought a new position in Celgene Corporation during the 2nd quarter valued at approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares in the last quarter. Rational Advisors LLC bought a new position in Celgene Corporation during the 2nd quarter valued at approximately $156,000. Finally, Oakworth Capital Inc. increased its position in Celgene Corporation by 11.7% during the 2nd quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 127 shares in the last quarter. Institutional investors own 79.23% of the company’s stock.
Celgene Corporation (NASDAQ:CELG) traded down 2.3878% on Friday, hitting $97.6024. The stock had a trading volume of 19,193,380 shares. Celgene Corporation has a 12 month low of $95.52 and a 12 month high of $147.17. The firm’s 50 day moving average price is $139.20 and its 200-day moving average price is $130.37. The stock has a market cap of $76.36 billion, a PE ratio of 30.2268 and a beta of 1.88.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the business earned $1.58 EPS. On average, analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.
In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,233 shares of company stock valued at $6,268,259. Company insiders own 0.95% of the company’s stock.
A number of analysts have commented on CELG shares. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a report on Tuesday, August 29th. Leerink Swann reaffirmed a “buy” rating and issued a $156.00 price objective on shares of Celgene Corporation in a report on Friday, October 20th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Friday, October 20th. Finally, Morgan Stanley cut their price objective on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating for the company in a report on Monday. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. Celgene Corporation currently has an average rating of “Buy” and a consensus target price of $143.45.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/celgene-corporation-celg-shares-bought-by-legal-general-group-plc.html.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.